Cross-sectional study about primary health care professionals views on the inclusion of the vaccine against human papillomavirus in the vaccine schedules

Infectious Agents and Cancer

Jesús S. Jiménez López¹  Laura P. Pérez Conde²  Sonia Yáñez Castaño²  Cristina Ruiz²  Ana Vazquez del Campo²  Victoria Bravo Violeta¹  M. Reyes Oliver Pérez¹ 

[1] Department of Gynecologic Oncology, Hospital Universitario 12 de Octubre, Avda Cordoba s/n, Madrid, Spain;Department of Obstetrics and Gynecology, School of Medicine, Complutense University, Madrid, Spain

关键词: Primary care;    Cervical cancer;    HPV vaccines;    Human papilloma virus;   

Others  :  1233700
DOI  :  10.1186/s13027-015-0034-9

 received in 2015-06-23, accepted in 2015-09-23,  发布年份 2015

【 摘 要 】

Background

Although the inclusion of the HPV vaccine has been registered in Spain since 2007, vaccination rates are lower than expected. The patients wish to be vaccinated is heavily influenced by information they have received from many source. The Knowledge of primary health care professionals affects the information provided to patients and is fundamental in the decision making. The aim of this study is to assess the opinions of primary health care professionals on the vaccine against HPV and their knowledge about HPV infection and its links to with gynecological and oropharyngeal cancer.

Methods

Cross-sectional study. A 19-item survey was drawn up. It included questions on basic aspects of HPV infection and marketed vaccines, personal opinion about the inclusion in the immunization schedules and their level of prescription and recommendation to patients in their clinical practice. From October 2013 to December 2013, 607 surveys were distributed among 20 primary health centers affiliated to the University Hospital 12 de Octubre. The results were analyzed using SPSS statistical package.

Results

One hundred sixty four successfully completed surveys were obtained for analysis. 89 % of the professionals knew about the relationship between HPV infection and cervical cancer, 57.3 % did not know any of the serotypes against which vaccines are targeted; 40.4 % believed that there is insufficient data to support the commercialization of the vaccines. Of these, 65.7 % argue that there is no data of its long-term effectiveness, 13.4 % that there is no data as to its side effects, 13.4 % believed that the cost effectiveness is not worthwhile.

Conclusions

There is a strong controversy among health professionals regarding the marketing and inclusion of HPV vaccine in immunization schedules. However, the knowledge of the primary care health professionals on key aspects of infection and vaccine protection are insufficient. The training of professionals in vaccination, cervical pathology and HPV infection should be improved to provide objective information on the use as this vaccine for patients.

【 授权许可】

   
2015 Pérez et al.

【 图 表 】

Fig. 1.

【 参考文献 】

• [1]Castellsagué X, Iftner T, Roura E, Vidart JA, Kjaer SK, Bosch FX, Muñoz N, Palacios S: San Martin Rodriguez M, Serradell L, Torcel-Pagnon L, Cortes J;CLEOPATRE Spain Study GroupCLEOPATRE Spain Study Group. Prevalence and genotype distribution of human papillomavirus infection of the cervix in Spain: The CLEOPATRE Study. J Med Virol 2012, 84(6):947-956.
• [2]Muñoz N, Castellsagué X, de Gonzalez AB, Gissman L: Champter 1: HPV in the etiology of human cáncer. Vaccine 2006, 24(Suppl 3):S1-S10.
• [3]Alemany L, Pérez C, Tous S, Llombart-Bosch A, Lloveras B, Lerma E, Guarch R, Andújar M, Pelayo A, Alejo M, Ordi J, Klaustermeier J, Velasco J, Guimerà N, Clavero O, Castellsagué X, Quint W, Muñoz N, Bosch FX, de Sanjosé S: Spanish study group RIS HPV TT. Human papillomavirus genotype distribution in cervical cancer cases in Spain. Implications for prevention. Gynecol Oncol 2012, 124:512-51.
• [4]Castellsagué X, Cohet C, Puig-Tintoré LM, Acebes LO, Salinas J, San Martin M, BreitscheidelL RV: Epidemiology and cost of treatment of genital warts in Spain. Eur J Public Health 2009, 19:106-10.
• [5]Castellsague X, Garland SM: A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine 2012, 30(Suppl 5):F123-F138.
• [6]De Sanjose S, Quint WG, Alemany L, Geraets DT, Klaustermeier JE, Lloveras B, Tous S, Felix A, Bravo LE, Shin HR, Vallejos CS, de Ruiz PA, Lima MA, Guimera N, Clavero O, Alejo M, Llombart-Bosch A, Cheng-Yang C, Tatti SA, Kasamatsu E, Iljazovic E, Odida M, Prado R, Seoud M, Grce M, Usubutun A, Jain A, Suarez GA, Lombardi LE, Banjo A, Menéndez C, Domingo EJ, Velasco J, Nessa A, Chichareon SC, Qiao YL, Lerma E, Garland SM, Sasagawa T, Ferrera A, Hammouda D, Mariani L, Pelayo A, Steiner I, Oliva E, Meijer CJ, Al-Jassar WF, Cruz E, Wright TC, Puras A, Llave CL, Tzardi M, Agorastos T, Garcia-Barriola V, Clavel C, Ordi J, Andújar M, Castellsagué X, Sánchez GI, Nowakowski AM, Bornstein J, Muñoz N, Bosch FX: Retrospective International Survey and HPV Time Trends Study Group. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol 2010, 11(11):1048-1056.
• [7]Olsson SE, Villa LL, Costa RL, Petta CA, Andrade RP, Malm C, Iversen OE, Høye J, Steinwall M, Riis-Johannessen G, Andersson-Ellstrom A, Elfgren K, von Krogh G, Lehtinen M, Paavonen J, Tamms GM, Giacoletti K, Lupinacci L, Esser MT, Vuocolo SC, Saah AJ, Barr E: Induction of immune memory following administrationof a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-likeparticle (VLP) vaccine. Vaccine 2007, 25:4931-9.
• [8]Limia A, Pachón I. Coverage of human papillomavirus vaccination during the first year of its introduction in Spain. Euro Surveill 2011;16(21):pii = 19873.
• [9]Black LL, Short MB, Sturm L, Rosenthal SL: Literature review of human papillomavirus vaccine acceptability among women over 26 years. Vaccine. 2009, 27:1668-73.
• [10]Wu JP, Porch E, McWeeney M, Ohman-Strickland P, Levine JP: Knowledge and concerns related to the human papillomavirus vaccine among underserved Latina women. J Low Genit Tract Dis. 2010, 14:155-61.
• [11]Dillner J, Kjaer SK, Wheeler CM, Sigurdsson K, Iversen OE, Hernández-Ávila M, Perez G, Brown DR, Koutsky LA, Tay EH, García P, Ault KA, Garland SM, Leodolter S, Olsson SE, Tang GW, Ferris DG, Paavonen J, Lehtinen M, Steben M, Bosch FX, Joura EA, Majewski S, Muñoz N, Myers ER, Villa LL, Taddeo FJ, Roberts C, Tadesse A, Bryan JT, Maansson R, Lu S, Vuocolo S, Hesley TM, Barr E, Haupt R: Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial. BMJ. 2010, 341:c3493.
• [12]Wheeler CM, Castellagué X, Garland SM, Szarewski A, Paavonen J, Naud P, Salmerón J, Chow SN, Apter D, Kitchener H, Teixeira JC, Skinner SR, Jaisamrarn U, Limson G, Romanowski B, Aoki FY, Schwarz TF, Poppe WA, Bosch FX, Harper DM, Huh W, Hardt K, Zahaf T, Descamps D, Struyf F, Dubin G, Lehtinen M: HPV PATRICIA Study Group: Cross-protective efficacy of HPV-16/18 AS04- adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of- study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 2012, 13:100-10.
• [13]Muñoz N, Méndez F, Posso H, Molano M, Van den Brule AJ, Ronderos M, Muñoz A: Incidence, duration, and determinants of cervical human papillomavirus infection in a cohort of Colombian women with normal cytological results. J Infect Dis 2004, 190(12):2077-87.
• [14]Sellors JW, Karwalajtys TL, Kaczorowski J, Mahony JB, Lytwyn A, Chong S, Sparrow J, Lorincz A: Incidence, clearance and predictors of human papillomavirus infection in women. CMAJ 2003, 168(4):421-5.
• [15]Castellagué X, Muñoz N, Pitisuttithum P, Ferris D, Monsonego J, Ault K, Luna J, Myers E, Mallary S, Bautista OM, Bryan J, Vuocolo S, Haupt RM, Saah A: End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24–45 years of age. Br J Cancer 2011, 105(1):28-37.
• [16]Muñoz N, Manalastas R Jr, Pitisuttithum P, Tresukosol D, Monsonego J, Ault K, Clavel C, Luna J, Myers E, Hood S, Bautista O, Bryan J, Taddeo FJ, Esser MT, Vuocolo S, Haupt RM, Barr E, Saah A: Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24–45 years: a randomised, double-blind trial. Lancet. 2009, 373:1949-57.
• [17]Cortés J, Martinón-Torres F, Ramón y Cajal JM, Ferret G, Gil A: Considerations on the clinical application of the human papillomavirus vaccine in Spain. Hum Vaccines 2011, 7(5):585-9.
• [18]Cortés Bordoy J: Vaccination against the human papilloma virus. Consensus statement 2011 of the scientific Spanish societies. Semergen 2012, 38(5):312-26.
• [19]Naud PS, Roteli-Martins CM, De Carvalho NS, Teixeira JC, de Borba PC, Sanchez N, Zahaf T, Catteau G, Geeraerts B, Descamps D: Sustained efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine: final analysis of a long-term follow-up study up to 9.4 years post-vaccination. Hum Vaccin Immunother 2014, 10(8):2147-62.
• [20]David M-P, Van Herck K, Hardt K, Tibaldi F, Dubin G, Descamps D, Van Damme P: Long-term persistence of antiHPV-16 and −18 antibodies induced by vaccination with the AS04- adjuvanted cervical cancer vaccine: modelling of sustained antibody responses. Gynecol Oncol 2009, 115(Supple3):S1-6.
• [21]Chao C, Klein NP, Velicer CM, Sy LS, Slezak JM, Takhar H, Ackerson B, Cheetham TC, Hansen J, Deosaransingh K, Emery M, Liaw KL, Jacobsen SJ: Surveillance of autoimmune conditions following rou- tine use of quadrivalent human papillomavirus vaccine. J Intern Med 2012, 271:193-203.
• [22]Agorastos T, Chatzigeorgiou K, Brotherton JM, Garland SM: Safety of human papillomavirus (HPV) vaccines: a review of the international experience so far. Vaccine 2009, 27:7270-81.
• [23]Ginsberg GM, Edejer TT, Lauer JA, Sepulveda C: Screening, prevention and treatment of cervical cancer-A global and regional generalized cost-effectiveness analysis. Vaccine 2009, 27(43):6060-79.
• [24]Largerón N, Rémy V, Oyee J, San-Martín M, Cortés J, Olmos L: Análisis de coste- efectividad de la vacunación frente al virus del papiloma humano tipos 6, 11, 16 y 18 en España. Vacunas 2008, 9:3-11.
• [25]Castellsaué X, San Martín M, Cortés J, Gonzalez A, Remy V: Impacto de la vacuna tetravalente frente al virus del papiloma humano (VPH) tipos 6,11,16 y 18 en las enfermedades asociadas al VPH en España. Prog Obsttet Ginecol. 2008, 51:520-30.
• [26]Torné A, Bayas J, Castellsagué X, Castro M, García E, Martínez J: Vacunación frente al cáncer de cérvix en mujeres fuera de los programas de vacunación sistemática, con o sin infección por el virus del papiloma humano o lesión cervical. Encuesta de opinión y recomendaciones. Prog Obstet Ginecol 2012, 55:10-31.
• [27]Mazzadi A, Palomino M, Arrossi S: Aceptabilidad y conocimientos sobre la vacunación contra el virus del papiloma humano (VPH) en médicos ginecólogos de Argentina. Salud Pública Mex 2012, 54:515-522.